Skip to main content

Table 12 Selected phase I-II clinical trials conducted with Obatoclax as a single (−single-) or combined therapeutic in untreated/pre-treated or non-refractory(−)/refractory (Refrac) patients with Carboplatin (CARB), Etoposide (ETOP) or Topotecan (TOPOT) against extensive-stage small cell lung cancer (es-SCLC), Myelodysplastic Syndrome (MDS), Hodgkin’s Lymphoma (HL), Myelofibrosis (MFS), advanced Chronic Lymphocytic Leukemia (a-CLL), and Hematologic Malignancies (HM). Adverse effects are abbreviated as Neut (Neutropenia), Anem (Anemia), Euph (Euphoria), Dizz (Dizziness), Naus (Nausea), Atax (Ataxia) and Throm (Thrombocytopenia). Disease stabilization effects on patient numbers (expressed as a percentage (%) of the whole group or as positive responders/group size) are highlighted in weeks (>wks). Unavailable data for disease stabilization effects is highlighted by ‘-‘. The clinical trials reference numbers highlighted in bold (left column) and their corresponding references highlighted in the columns on the right (Ref)

From: BH3-mimetics: recent developments in cancer therapy

Obatoclax Phase Patients Refrac Combined Disease Adverse Effects Stabilization Ref
NCT00684918 I/II Untreated -single- AML Neut 4/19 for 11 cycles [408]
NCT00682981 II Untreated CARB/ETOP es-SCLC Neut/Anem [409]
NCT00413114 II Untreated -single- MDS Euph/Naus 50% (> 12 wks) [410]
NCT00359892 II Yes -single- HL Euph/Dizz 38% (> 8 wks) [411]
NCT00521144 II Pre-treated Yes TOPOT SCLC Throm/Neut/Anem/Atax 56% (Phase II) [412]
NCT00360035 II Pre-treated -single- MFS Atax/Anem/Throm [413]
NCT00600964 I/II Pre-treated Yes (22/26) -single- a-CLL Atax/Euph/Anem/
NCT00438178 I N/A Yes -single- HM Neut/Anem/Throm [415]